COVID-19: FDA Expected To Authorize Booster Shots For Immunocompromised People COVID-19: FDA Expected To Authorize Booster Shots For Immunocompromised People
Covid-19: FDA Expected To Authorize Booster Shots For Immunocompromised People The US Food and Drug Administration is expected to move forward quickly with authorization of COVID-19 booster shots for some Americans who are immunocompromised, according to reports. Health officials said that the third shot of the current two-dose Pfizer and Moderna vaccine could be authorized within the next 48 hours, though no official timetable has been set as variants of the virus and COVID-19 mutations continue to cause a surge in new cases. Before a vaccine can be used in new ways outside existing authorization it requires new approval from the FDA. Currently, the Moderna, Pfizer…
COVID-19: Unvaccinated Are More Than Twice As Likely To Get Virus A Second Time, CDC Says COVID-19: Unvaccinated Are More Than Twice As Likely To Get Virus A Second Time, CDC Says
Covid-19: Unvaccinated Are More Than Twice As Likely To Get Virus A Second Time, CDC Says A new study by the US Centers for Disease Control and Prevention (CDC) found that COVID-19 vaccines offer better and more protection against reinfection of the virus than just natural immunity among those who already have been infected. On Friday, Aug. 6, the CDC released the findings of a new study of nearly 1,000 Americans who previously tested positive for COVID-19 but remained unvaccinated. According to the study, those who were unvaccinated proved to be more than twice as likely to become infected for a second time than those who were fully vaccinated against the virus. Researchers …
COVID-19: Studies Determine How Effective Moderna Vaccine Is Six Months After Second Dose COVID-19: Studies Determine How Effective Moderna Vaccine Is Six Months After Second Dose
Covid-19: Studies Determine How Effective Moderna Vaccine Is Six Months After Second Dose The Moderna COVID-19 vaccine has proven to be largely effective six months after Americans receive a second dose, according to recent studies conducted by the pharmaceutical company. Moderna CEO Stéphane Bancel announced this week that the latest round of studies into the vaccine found that it maintains 93 percent of its efficacy six months after the second dose is administered. Bancel said that while the vaccine remains effective, it is important to recognize the threat of variants of the virus, specifically the more transmissible Delta variant, which has been rapidly spreading across the …
COVID-19: Cape Cod Cluster Linked To Delta Variant Grows To 430 Cases COVID-19: Cape Cod Cluster Linked To Delta Variant Grows To 430 Cases
Covid-19: Cape Cod Cluster Linked To Delta Variant Grows To 430 Cases Click here for an updated story - COVID-19: Cape Cod Cluster Among Vaccinated Led To Mask Shift; CDC Says 'The War Has Changed' The highly contagious Delta variant has become a major cause of concern in a Cape Cod community following a recent breakout of new COVID-19 infections. There are now more than 430 active cases of COVID-19 in Provincetown as of Tuesday, July 27, more than triple the cases reported last week, most of which have been linked to the variant. According to the Massachusetts Department of Public Health, genetic sequencing of initial samples associated with the recent …
COVID-19: FDA To Announce J&J Vaccine Has Been Linked To Rare Disorder, Report Says COVID-19: FDA To Announce J&J Vaccine Has Been Linked To Rare Disorder, Report Says
Covid-19: FDA To Announce J&J Vaccine Has Been Linked To Rare Disorder, Report Says The Food and Drug Administration is reportedly getting ready to announce a warning that the Johnson & Johnson COVID-19 vaccine has been linked to a rare autoimmune disorder. The Washington Post reported on Monday, July 12, that the Centers for Disease Control and Prevention said about 100 reports of Guillain-Barré syndrome have been detected among people who have received the Johnson & Johnson vaccine in the United States.  More than 12.8 million doses of the Johnson & Johnson vaccine have been administered in the U.S., the CDC reported. The Mayo Clinic said…
COVID-19: New Variant May Be More Resistant To Vaccines Than Other Strains, Scientists Say COVID-19: New Variant May Be More Resistant To Vaccines Than Other Strains, Scientists Say
Covid-19: New Variant May Be More Resistant To Vaccines Than Other Strains, Scientists Say A new strain of the COVID-19 virus may be more resistant to vaccines than other variants, scientists are now warning. The C.37 strain, known as the Lambda variant, was first identified in Peru in December 2020, when it accounted for less than one percent of new cases. It now accounts for about 80 percent of new infections in Peru and has spread to about 27 countries in the last month, according to a report in the Financial Times. The World Health Organization said the strain carries a number of mutations that may have prompted potential increased transmissibility or possible increased resi…
COVID-19: New Study Reveals How Long Protection From Pfizer, Moderna Vaccines Could Last COVID-19: New Study Reveals How Long Protection From Pfizer, Moderna Vaccines Could Last
Covid-19: New Study Reveals How Long Protection From Pfizer, Moderna Vaccines Could Last Claims that booster shots could be required in several months for those receiving the Moderna and Pfizer COVID-19 vaccine may have been overblown, according to new reports. New findings in a study published this week showed that both COVID-19 vaccines have shown a “persistent” immune response to the virus that could potentially last years. The last looming question is how effective the vaccines are against variants of the virus, specifically the more transmissible Delta strain that has become dominant in the US and is present in 49 states. Related story - COVID-19: Parts Of US With Low Va…
COVID-19: CDC Reveals Percentage Of Americans Who Haven't Gotten Second Dose COVID-19: CDC Reveals Percentage Of Americans Who Haven't Gotten Second Dose
Covid-19: CDC Reveals Percentage Of Americans Who Haven't Gotten Second Dose A significant number of Americans who received their first COVID-19 shot have missed their second dose, causing concern as the number of new cases from the Delta variant grows, according to the Centers for Disease Control and Prevention (CDC). The CDC said this week that more than 10 percent of Americans have received just one dose and opted to skip the second vaccine, which could prove problematic as the more transmissible Delta COVID-19 variant continues to rapidly spread and become more dominant. According to the CDC, just 88 percent of those who received one dose of the Moderna or Pfize…
COVID-19: Pop-Up, Walk-In Vaccination Clinic Planned In Westchester COVID-19: Pop-Up, Walk-In Vaccination Clinic Planned In Westchester
Covid-19: Pop-Up, Walk-In Vaccination Clinic Planned In Westchester There will be a COVID-19 pop-up vaccination site set up in Westchester as the county continues its recovery from the pandemic. Officials announced that from 10 a.m. to 1 p.m. on Friday, June 18, the clinic will be held at the Westchester County Department of Health Clinic at 134 Court St. in White Plains. The pop-up is for walk-ins 18 and older and the Pfizer and Moderna vaccines will both be available. Like the rest of New York, Westchester is enjoying a revival as it recovers from COVID-19, with the county Department of Health reporting just 300 active cases, down from thousands earlier …
COVID-19: New US-Made Vaccine Has 90 Percent Efficiency Rate, Can Be Stored In Refrigerators COVID-19: New US-Made Vaccine Has 90 Percent Efficiency Rate, Can Be Stored In Refrigerators
Covid-19: New Us-made Vaccine Has 90 Percent Efficiency Rate, Can Be Stored In Refrigerators An American biotech company announced that it has concluded the latest phase of clinical trials for its COVID-19 vaccine, which has proven to be highly effective. Novavax announced on Monday, June 14 that its vaccine has an overall efficacy rate of 90.4 percent in a Phase 3 trial that took place across the United States and Mexico. The Novavax vaccine can be stored in standard refrigerators, making it easier to distribute. Additional analysis of the trial is ongoing, according to the company, and will be submitted to peer-reviewed journals for publication. 
The company said that the vacc…
COVID-19: Moderna Asks FDA To Approve Vaccines For Those Ages 12 To 17 COVID-19: Moderna Asks FDA To Approve Vaccines For Those Ages 12 To 17
Covid-19: Moderna Asks FDA To Approve Vaccines For Those Ages 12 To 17 Moderna has requested an emergency use authorization from the Food and Drug Administration (FDA) for its COVID-19 vaccine in adolescents between the ages of 12 and 17. The company announced that clinical trials have shown that the vaccine has a 93 percent efficacy rate among adolescents, and has been proven to be safe. If approved, it would be the second COVID-19 vaccine authorized for adolescents, joining the Pfizer-BioNTech vaccine, which was given the green light for use earlier this month. In their study, Moderna found no cases of COVID-19 in participants who received two doses of th…
COVID-19: Vaccine 'Safe, Highly Effective' In Kids 12-17, Moderna Says, Will Seek FDA Approval COVID-19: Vaccine 'Safe, Highly Effective' In Kids 12-17, Moderna Says, Will Seek FDA Approval
Covid-19: Vaccine 'Safe, Highly Effective' In Kids 12-17, Moderna Says, Will Seek FDA Approval Moderna’s COVID-19 vaccine has proven effective and safe for adolescents and teens between the ages of 12 and 17, the company announced, as it prepares to seek federal authorization. The company announced that clinical trials have shown that the vaccine has a 93 percent efficacy rate among adolescents, and has been proven to be safe. Moderna officials said that they plan to apply for federal approval from the Food and Drug Administration (FDA) to use the vaccine in that age group in June. If approved, it would be the second COVID-19 vaccine authorized for adolescents, joining the Pfizer-Bi…